General Discussions

Do BTK Inhibitors Lead to Secondary Cancers?

By David A. Bond, MD
PUBLISHED WEDNESDAY, DECEMBER 31, 1969


Patients with chronic lymphocytic leukemia who take BTK inhibitors tend to have a higher rate of secondary cancers than the general population, explained David A. Bond, MD, an assistant professor at The Ohio State University. 

In a study including 691 patients, Bond and his team catalogued secondary cancer instances, and found that these diagnoses were the second leading cause of death in the population. 
Start a discussion
You must log in to use this feature, please click here to login.
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Newsroom
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.